Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amuc_1434
- Development stage
- Preclinical
- Lead developer
- Kaken Pharmaceutical
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Amuc_1434 is a recombinant aspartic protease protein derived from the gut bacterium Akkermansia muciniphila. It has been studied primarily for its antitumor effects in colorectal cancer models. Mechanistically, Amuc_1434 degrades Mucin2 (MUC2), a major component of the intestinal mucus layer that is highly expressed in certain colorectal cancers. This degradation leads to inhibition of tumor cell proliferation, induction of cell cycle arrest at G0/G1 phase, upregulation of p53 expression, increased mitochondrial reactive oxygen species (ROS), and loss of mitochondrial membrane potential. Critically, it promotes apoptosis via activation of both death receptor and mitochondrial pathways by upregulating tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Additionally, studies indicate that outer membrane vesicles containing Amuc_1434 can modulate PD-L1 expression and enhance CD8+ T cell-mediated antitumor immunity[1][2][3][7].
- Other names
- Akkermansia muciniphila Aspartic Protease Amuc_1434Amuc_1434*
Beyond the preview
Go deeper on Amuc_1434.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amuc_1434.